239 related articles for article (PubMed ID: 8676252)
1. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis.
Clohisy DR; Palkert D; Ramnaraine ML; Pekurovsky I; Oursler MJ
J Orthop Res; 1996 May; 14(3):396-402. PubMed ID: 8676252
[TBL] [Abstract][Full Text] [Related]
2. Localized, tumor-associated osteolysis involves the recruitment and activation of osteoclasts.
Clohisy DR; Ogilvie CM; Carpenter RJ; Ramnaraine ML
J Orthop Res; 1996 Jan; 14(1):2-6. PubMed ID: 8618161
[TBL] [Abstract][Full Text] [Related]
3. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway.
Bendre MS; Margulies AG; Walser B; Akel NS; Bhattacharrya S; Skinner RA; Swain F; Ramani V; Mohammad KS; Wessner LL; Martinez A; Guise TA; Chirgwin JM; Gaddy D; Suva LJ
Cancer Res; 2005 Dec; 65(23):11001-9. PubMed ID: 16322249
[TBL] [Abstract][Full Text] [Related]
4. Tumor osteolysis in osteopetrotic mice.
Clohisy DR; Ogilvie CM; Ramnaraine ML
J Orthop Res; 1995 Nov; 13(6):892-7. PubMed ID: 8544026
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
[TBL] [Abstract][Full Text] [Related]
6. Osteoclasts are required for bone tumors to grow and destroy bone.
Clohisy DR; Ramnaraine ML
J Orthop Res; 1998 Nov; 16(6):660-6. PubMed ID: 9877389
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer cell line MDA-231 stimulates osteoclastogenesis and bone resorption in human osteoclasts.
Grano M; Mori G; Minielli V; Cantatore FP; Colucci S; Zallone AZ
Biochem Biophys Res Commun; 2000 Apr; 270(3):1097-100. PubMed ID: 10772956
[TBL] [Abstract][Full Text] [Related]
8. Selective tyrosine kinase inhibition of insulin-like growth factor-1 receptor inhibits human and mouse breast cancer-induced bone cell activity, bone remodeling, and osteolysis.
Logan JG; Sophocleous A; Marino S; Muir M; Brunton VG; Idris AI
J Bone Miner Res; 2013 May; 28(5):1229-42. PubMed ID: 23239200
[TBL] [Abstract][Full Text] [Related]
9. Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor.
Chen Y; Zheng J; Mo L; Chen F; Li R; Wang Y; Liang Q; Chen Z; Dai W; Chen L; Yan P; Zhou H; Li X
Phytomedicine; 2024 Jul; 129():155688. PubMed ID: 38728920
[TBL] [Abstract][Full Text] [Related]
10. Identification of breast cancer cell line-derived paracrine factors that stimulate osteoclast activity.
Pederson L; Winding B; Foged NT; Spelsberg TC; Oursler MJ
Cancer Res; 1999 Nov; 59(22):5849-55. PubMed ID: 10582709
[TBL] [Abstract][Full Text] [Related]
11. Review of cellular mechanisms of tumor osteolysis.
Clohisy DR; Perkins SL; Ramnaraine ML
Clin Orthop Relat Res; 2000 Apr; (373):104-14. PubMed ID: 10810467
[TBL] [Abstract][Full Text] [Related]
12. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis.
Ohshiba T; Miyaura C; Inada M; Ito A
Br J Cancer; 2003 Apr; 88(8):1318-26. PubMed ID: 12698202
[TBL] [Abstract][Full Text] [Related]
13. Osteoclastic miR-214 targets TRAF3 to contribute to osteolytic bone metastasis of breast cancer.
Liu J; Li D; Dang L; Liang C; Guo B; Lu C; He X; Cheung HY; He B; Liu B; Li F; Lu J; Wang L; Shaikh AB; Jiang F; Lu C; Peng S; Zhang Z; Zhang BT; Pan X; Xiao L; Lu A; Zhang G
Sci Rep; 2017 Jan; 7():40487. PubMed ID: 28071724
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of zoledronate using an in vitro mimetic cellular model for breast cancer metastatic bone disease.
Dedes PG; Kanakis I; Gialeli Ch; Theocharis AD; Tsegenidis T; Kletsas D; Tzanakakis GN; Karamanos NK
Biochim Biophys Acta; 2013 Jun; 1830(6):3625-34. PubMed ID: 23395844
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer increases osteoclastogenesis by secreting M-CSF and upregulating RANKL in stromal cells.
Mancino AT; Klimberg VS; Yamamoto M; Manolagas SC; Abe E
J Surg Res; 2001 Sep; 100(1):18-24. PubMed ID: 11516200
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
Marino S; Bishop RT; Mollat P; Idris AI
Calcif Tissue Int; 2018 Aug; 103(2):206-216. PubMed ID: 29455416
[TBL] [Abstract][Full Text] [Related]
17. Gallium, a promising candidate to disrupt the vicious cycle driving osteolytic metastases.
Strazic-Geljic I; Guberovic I; Didak B; Schmid-Antomarchi H; Schmid-Alliana A; Boukhechba F; Bouler JM; Scimeca JC; Verron E
Biochem Pharmacol; 2016 Sep; 116():11-21. PubMed ID: 27378505
[TBL] [Abstract][Full Text] [Related]
18. Localized experimental bone metastasis drives osteolysis and sensory hypersensitivity at distant non-tumor-bearing sites.
Abdelaziz DM; Stone LS; Komarova SV
Breast Cancer Res Treat; 2015 Aug; 153(1):9-20. PubMed ID: 26208488
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease.
Bendre MS; Montague DC; Peery T; Akel NS; Gaddy D; Suva LJ
Bone; 2003 Jul; 33(1):28-37. PubMed ID: 12919697
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis.
Guise TA; Yin JJ; Taylor SD; Kumagai Y; Dallas M; Boyce BF; Yoneda T; Mundy GR
J Clin Invest; 1996 Oct; 98(7):1544-9. PubMed ID: 8833902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
